“Efficacy and Safety of Lebrikizumab Is Maintained to Two Years in Patients With Moderate-to-Severe Atopic Dermatitis”. 2023. SKIN The Journal of Cutaneous Medicine 7 (6): s271. https://doi.org/10.25251/skin.7.supp.271.